Ep. 31 - DiMe's Jennifer Goldsack скачать в хорошем качестве

Ep. 31 - DiMe's Jennifer Goldsack

The use of digital endpoints in clinical trials is expanding rapidly, and they will soon be included on drug labels, Digital Medicine Society CEO Jennifer Goldsack predicted in her conversation on #TheBioCenturyShow with Washington Editor Steve Usdin. The challenge and opportunity, according to Goldsack, is to use these new tools to redefine disease, rather than to replicate the often imprecise and unreliable metrics that are used in clinical medicine. Goldsack also discussed DiMe’s development of open-access digital tools for helping medical product developers enhance the diversity, equity and inclusion parameters of their work, and the rapid adoption of generative artificial intelligence tools such as ChatGPT. View full story: https://www.biocentury.com/article/64... ​‪@dimesociety4362‬ #biotech #pharma #biopharma #dimesociety 00:00 - Intro 01:18 – Redefining Healthcare 06:08 – Regulation & Reimbursement 15:39 – DEI Tools 23:43 – Safety in the Digital Age 27:05 – Building a Digital Workforce